Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, Cluepoints, offers his key ...

Are New Medicines Being Developed to Meet the Needs of the Ever-Ageing Population?

Are New Medicines Being Developed to Meet the Needs of the Ever-Ageing Population?

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

The conundrum of missing data vs. inter-rater variability.

Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...